Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?
- PMID: 35858498
- PMCID: PMC9254455
- DOI: 10.1016/j.msard.2022.104035
Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, mass vaccination was a beneficial strategy in many countries. Nevertheless, reports of serious complications such as postvaccination neuromyelitis optica spectrum disorder (NMOSD) raised concerns about the safety of vaccines. Anamnart and colleagues explained postvaccination NMOSD following different vaccines, including COVID-19. To emphasize the message of this article, in this letter, we present a unique case of postvaccination NMOSD with a fulminant and fatal course, which may show a plausible relationship between COVID-19 vaccination and triggering anti-aquaporin-4 antibody (AQP4-Ab).
Keywords: COVID-19 vaccine; NMOSD; Neuromyelitis optica spectrum disorder; Postvaccination.
Copyright © 2022. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures

Comment in
-
Fatal neuromyelitis optica after COVID-19 vaccination.Mult Scler Relat Disord. 2022 Dec;68:104089. doi: 10.1016/j.msard.2022.104089. Epub 2022 Aug 11. Mult Scler Relat Disord. 2022. PMID: 35987109 Free PMC article. No abstract available.
Similar articles
-
Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.Mult Scler Relat Disord. 2022 Feb;58:103414. doi: 10.1016/j.msard.2021.103414. Epub 2021 Nov 18. Mult Scler Relat Disord. 2022. PMID: 35216789
-
Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review.J Neuroimmunol. 2022 Dec 15;373:577994. doi: 10.1016/j.jneuroim.2022.577994. Epub 2022 Oct 28. J Neuroimmunol. 2022. PMID: 36332464
-
Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report.BMC Neurol. 2022 May 18;22(1):185. doi: 10.1186/s12883-022-02698-y. BMC Neurol. 2022. PMID: 35585528 Free PMC article.
-
Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19.Neurol Sci. 2021 Sep;42(9):3537-3539. doi: 10.1007/s10072-021-05427-4. Epub 2021 Jun 29. Neurol Sci. 2021. PMID: 34189662 Free PMC article.
-
First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2.Neurol Sci. 2023 Feb;44(2):451-455. doi: 10.1007/s10072-022-06465-2. Epub 2022 Oct 27. Neurol Sci. 2023. PMID: 36289118 Free PMC article.
Cited by
-
Clinical Research into Central Nervous System Inflammatory Demyelinating Diseases Related to COVID-19 Vaccines.Diseases. 2024 Mar 20;12(3):60. doi: 10.3390/diseases12030060. Diseases. 2024. PMID: 38534984 Free PMC article.
-
Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis.Front Immunol. 2023 Jun 6;14:1177127. doi: 10.3389/fimmu.2023.1177127. eCollection 2023. Front Immunol. 2023. PMID: 37346048 Free PMC article.
-
Causal relationships between susceptibility and severity of COVID-19 and neuromyelitis optica spectrum disorder (NMOSD) in European population: a bidirectional Mendelian randomized study.Front Immunol. 2023 Dec 4;14:1305650. doi: 10.3389/fimmu.2023.1305650. eCollection 2023. Front Immunol. 2023. PMID: 38111568 Free PMC article.
-
Neurological Disorders following COVID-19 Vaccination.Vaccines (Basel). 2023 Jun 19;11(6):1114. doi: 10.3390/vaccines11061114. Vaccines (Basel). 2023. PMID: 37376503 Free PMC article. Review.
-
Fatal neuromyelitis optica after COVID-19 vaccination.Mult Scler Relat Disord. 2022 Dec;68:104089. doi: 10.1016/j.msard.2022.104089. Epub 2022 Aug 11. Mult Scler Relat Disord. 2022. PMID: 35987109 Free PMC article. No abstract available.
References
-
- Anamnart C, Tisavipat N, Owattanapanich W, Apiwattanakul M, Savangned P, Prayoonwiwat N, et al. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review. Mult. Scler. Relat. Disord. 2022;58 https://linkinghub.elsevier.com/retrieve/pii/S2211034821006805 Available from: - PubMed
-
- Awad A, Stüve O. Review: Cyclophosphamide in multiple sclerosis–Scientific rationale, history and novel treatment paradigms. Ther. Adv. Neurol. Disord. 2009;2(6):357–368. http://journals.sagepub.com/doi/10.1177/1756285609344375 Available from: - DOI - PMC - PubMed
-
- Krumbholz M, Hofstadt-van Oy U, Angstwurm K, Kleiter I, Jarius S, Paul F, et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J. Neurol. 2015;262(5):1379–1384. http://link.springer.com/10.1007/s00415-015-7766-8 Available from: - DOI - PMC - PubMed
-
- Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. https://www.neurology.org/lookup/doi/10.1212/WNL.0000000000001729 Available from: - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical